New York Class Action Alleges Big Pharma Companies Of Engaging In Conspiracy And Antitrust Behavior In A Bid To Control Insulin Prices
Pharmaceutical bigwigs AstraZeneca, Sanofi, Novo Nordisk, and Eli Lilly are facing antitrust violations after they allegedly conspired with one another to increase the price of insulin medication for patients that are in poverty and reside in poor areas.
Clinics For The Needy Fight Back Against Alleged Corporate Control Over Life-saving Drug
The class action lawsuit was brought up against the quartet by a New York group dubbed as Mosaic Health, a collective of more than twenty health clinics and providers who mostly serve the needy and patients belonging in the low-income bracket.
The Insulin Antitrust Lawsuit contends that the four deliberately dropped out of a key federal public health law to jack up their prices using their dominance in the field of pharmaceuticals as leverage.
Known as the 340B Drug Discount, complainant Mosaic Health shared that AstraZeneca, Sanofi, Novo Nordisk, and Eli Lilly formerly honored their commitment to providing discounted insulin medication prices to them and other health clinics as mandated by the law.
However, the quad reportedly dropped the ball and ceased giving lower prices to medical facilities in 2020. The reason behind the move? The big pharmaceutical players retorted that they were not required to participate in discounted drugs program; hence they backed off.
As a result, countless medical providers giving service to the poor were gravely affected by the move soon after. The Insulin Antitrust Lawsuit explained that the majority of facilities that are negatively impacted by the companies’ decisions were funded by the federal government.
Insulin Antitrust Class Action Lawsuit Brief
The class action lawsuit accused defendants AstraZeneca, Sanofi, Novo Nordisk, and Eli Lilly of turning their attention to different safety-net clinics and small contract pharmacies in the country after a failed attempt to force the government to eliminate drug discount programs for their benefit.
Reports and observers agree that giants in the pharmaceutical industry have been trying to have their share from the enforcement of drug discounts by the federal government. It is said that many companies have been trying to lobby very hard to change the legislation for their own financial benefit.
This is not the first time an antitrust class action has been brought against drug manufacturers in relation to their alleged control on how they price life-saving medication such as insulin.
Defendants in this particular case Eli Lilly, Sanofi, and Novo Nordisk, were slapped with antitrust class litigation in 2017, arguing that the three have worked with one another to deliberately increase the prices of their insulin drug offering that left many suffering patients at risk of severe health complications.
Consider The Consumer will continue to report on this matter as soon as the court releases any updates.
Editor’s Note on Insulin Antitrust Lawsuit – Sanofi & Other Pharma Giants Conspired To Control Insulin Prices:
This article feature discusses the class action lawsuit filed against different players in the drug industry that are accused of conducting illegal activities to take over control of insulin prices. Recently Pfizer agreed for a $345 million settlement over Epipen monopoly.
Case Name(s) & No.: Mosaic Health, Inc. v. Sanofi-Aventis U.S., LLC, et al.; Case No.: 6:21-cv-06507
Jurisdiction: United States (U.S.) District Court for the Western District of New York
Products/Services Involved: Insulin medication offered by pharmaceutical companies AstraZeneca, Sanofi, Novo Nordisk, and Eli Lilly
Allegation(s): Drug manufacturers are alleged to engage in potential antitrust violations that are said to pose life-threatening impacts on millions of patients in an attempt to maintain their control over insulin drug prices.
What are your thoughts on this piece? Please send us a message by clicking the ‘Contact Us’ button below! We’d love to hear back from you.